Management of muscle invasive bladder cancer—British approaches to organ conservation

Abstract

British groups have long favored a more conservative approach to the management of invasive bladder cancer. They have been involved in several randomized trials looking at the efficacy of these approaches and have also been leaders in the study of neoadjuvant chemotherapy. This article documents the concerns that linger over the efficacy and morbidity of cisplatin-based chemotherapy and describes a national trial investigating a potentially less morbid 5FU and mitomycin alternative.